CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 177 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $37,934,916 | -8.7% | 1,275,552 | -44.7% | 4.24% | -0.9% |
| Q2 2023 | $41,546,155 | +112105.0% | 2,305,558 | 0.0% | 4.28% | -7.5% |
| Q1 2023 | $37,027 | -12.2% | 2,305,558 | 0.0% | 4.63% | -1.8% |
| Q4 2022 | $42,192 | -99.9% | 2,305,558 | 0.0% | 4.72% | -12.8% |
| Q3 2022 | $45,281,000 | +5.3% | 2,305,558 | 0.0% | 5.40% | +7.2% |
| Q2 2022 | $42,999,000 | -3.5% | 2,305,558 | +13.6% | 5.04% | +16.5% |
| Q1 2022 | $44,552,000 | -22.7% | 2,029,701 | 0.0% | 4.33% | -5.4% |
| Q4 2021 | $57,664,000 | +63.1% | 2,029,701 | +20.8% | 4.57% | +108.5% |
| Q3 2021 | $35,358,000 | +11.7% | 1,679,701 | 0.0% | 2.19% | +5.7% |
| Q2 2021 | $31,662,000 | +93.4% | 1,679,701 | +56.8% | 2.08% | +123.8% |
| Q1 2021 | $16,371,000 | +8.3% | 1,071,428 | 0.0% | 0.93% | -2.3% |
| Q4 2020 | $15,118,000 | -10.0% | 1,071,428 | 0.0% | 0.95% | -39.4% |
| Q3 2020 | $16,789,000 | -10.6% | 1,071,428 | 0.0% | 1.56% | -20.4% |
| Q2 2020 | $18,771,000 | – | 1,071,428 | – | 1.97% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 623,819 | $11,336,501 | 9.41% |
| Finepoint Capital LP | 822,745 | $15,056 | 4.87% |
| Bain Capital Life Sciences Investors, LLC | 2,305,558 | $42,192 | 4.72% |
| Opaleye Management Inc. | 732,000 | $13,395,600 | 4.66% |
| 5AM Venture Management, LLC | 862,286 | $15,779,834 | 4.24% |
| SPHERA FUNDS MANAGEMENT LTD. | 671,644 | $12,291,085 | 2.64% |
| First Light Asset Management, LLC | 1,329,313 | $24,326,428 | 2.26% |
| BRAIDWELL LP | 3,469,674 | $63,495,034 | 2.13% |
| BVF INC/IL | 2,736,613 | $50,080,018 | 2.11% |
| Perceptive Advisors | 4,039,276 | $73,918,751 | 2.08% |